CDXS
Codexis, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.38
P/S
2.44
EV/EBITDA
-6.46
DCF Value
$-4.15
FCF Yield
-13.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
79.5%
Operating Margin
-54.5%
Net Margin
-62.5%
ROE
-90.5%
ROA
-29.8%
ROIC
-30.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $38.9M | $9.6M | $0.11 |
| FY 2025 | $70.4M | $-44.0M | $-0.50 |
| Q3 2025 | $8.6M | $-19.6M | $-0.22 |
| Q2 2025 | $15.3M | $-13.3M | $-0.16 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.08
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.